Abstract：Objective To study the efficacy and safety of Cefotaxime Sodium in the adjuvant treatment of severe community acquired pneumonia(CAP)in children.Methods Altogether 78 children with severe CAP treated in Huanggang Maternity and Children Health Care Hospital from June 2019 to December 2020 were selected as the research object,and they were divided into the control group(39 cases)and the observation group(39 cases)according to random number table method.The control group was treated with routine treatment,and the observation group was treated with Cefotaxime Sodium on the basis of the control group.The improvement time of clinical symptoms,serum inflammatory factors,immune function indexes,clinical efficacy and adverse reactions were compared between the two groups.Results The improvement time of fever,cough and pulmonary rale in the observation group were shorter than those in the control group,with statistically significant differences (P＜0.05).After treatment,the levels of serum C-reactive protein(CRP),serum procalcitonin(PCT),interleukin(IL)-6 and leukocyte clusters of differentiation 8+(CD8+)in the observation group were lower than those in the control group,the levels of CD3+,CD4+and the total clinical effective rate after treatment in the observation group were higher than those in the control group,with statistically significant differences(P＜0.05).There was no statistically significant difference in the incidence of adverse reactions between the two groups(P＞0.05).Conclusion Application of Cefotaxime Sodium in the adjuvant treatment of children with severe CAP can promote the improvement of clinical efficacy,help to improve clinical symptoms and reduce inflammatory reaction,with high drug safety.
李锦梧. 头孢噻肟钠辅助治疗儿童重症社区获得性肺炎的效果及安全性[J]. 中国当代医药, 2021, 28(33): 122-125.
LI Jin-wu. Efficacy and safety of Cefotaxime Sodium in the adjuvant treatment of severe community-acquired pneumonia in children. 中国当代医药, 2021, 28(33): 122-125.
京公网安备 11010502046607号